Fluvastatin blunts the effect of a high-fat meal on plasma triglyceride and high-sensitivity C-reactive protein concentrations in patients at high risk for cardiovascular events

Coronary Artery Disease

Volumn 18, Issue 6, 2007, Pages 489-493

  Liu, Ling ^a   Zhao, Shui Ping ^a   Hu, Min ^a   Li, Ji Xiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cardiovascular events; Fluvastatin; High risk; High fat meal; High sensitivity C reactive protein

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID DIET; MALE; OUTCOME ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIETARY FATS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RISK FACTORS; TRIGLYCERIDES;

EID: 34547908478     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328258fe41     Document Type: Article

References (14)

1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
2. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002; 39:1145-1150.
3. Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003; 49:1347-1352.
4. Igarashi M, Hirata A, Yamauchi T, Yamaguchi H, Tsuchiya H, Ohnuma H, et al. Clinical utility and approach to estimate postprandial hypertriglycemia by a newly designed oral fat-loading test. J Atheroscler Thromb 2003; 10: 314-320.
5. Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxidative stress on endothelial function after a high-fat meal. Clin Sci (Lond) 2004; 106:315-319.
6. Zahedi RG, Summers LK, Lumb P, Chik G, Crook MA. The response of serum sialic acid and other acute phase reactants to an oral fat load in healthy humans. Eur J Intern Med 2001; 12:510-514.
7. Carroll MF, Schade DS. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. Circulation 2003; 108:24-31.
8. Plenge JK, Hernandez TL,Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447-1452.
9. Chi DS, Jin FX, Yang SG, Su YW, Ge B, Zhang J, et al. Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia. Di Yi Jun Yi Da Xue Xue Bao 2002; 22:1109-1111.
10. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17:1513-1517.
11. Hyson DA, Paglieroni TG, Wun T, Rutledge JC. Postprandial lipemia is associated with platelet and monocyte activation and increased monocyte cytokine expression in normolipemic men. Clin Appl Thromb Hemost 2002; 8:147-155.
12. Gronholdt ML, Sillesen H, Wiebe BM, Laursen H, Nordestgaard BG. Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. Eur J Vasc Endovasc Surg 2001; 21:227-234.
13. Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment. Thromb Haemost 2000; 83:549-453.
14. Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002; 23:794-799.